The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Open accessAbstract
Background Sickle cell anaemia (SCA) is associated with significant morbidity from acute complications and organ dysfunction beginning in the first year of life. In the first multicenter randomised double-blinded trial in very young children with SCA, the impact of hydroxyurea (hydroxycarbamide) therapy on organ dysfunction, clinical complications, and laboratory findings, and its toxicity, were examined. Methods Eligible subjects had HbSS or Sβ0thalassaemia, were age 9–18 months at randomisation, and were not selected for clinical severity. Subjects received liquid hydroxyurea, 20 mg/kg/day, or placebo for two years. Primary study endpoints were splenic function (qualitative uptake on 99Tc spleen scan) and renal function (glomerular filtration rate by 99mTc-DTPA clearance). Additional evaluations included: blood counts, HbF, chemistry profiles, spleen function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, growth, and mutagenicity. Study visits occurred every two to four weeks. Findings Ninety-six subjects received hydroxyurea and 97 placebo; 86% completed the study. Significant differences were not seen for the primary endpoints, but suggestive benefit was noted in quantitative measures of spleen function. Hydroxyurea significantly decreased pain and dactylitis with trends for decreased acute chest syndrome, hospitalisation and transfusion. Hydroxyurea increased haemoglobin and HbF and decreased WBC count. Toxicity was limited to mild-moderate neutropaenia. Interpretation Although hydroxyurea treatment did not reduce splenic and renal dysfunction assessed by primary endpoint measures, it resulted in major clinical benefit because of diminished acute complications, favorable haematologic results, and a lack of unexpected toxicities. Based on the safety and efficacy data from this trial, hydroxyurea can now be considered for all very young children with SCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, all children seem to have a robust HbF response to hydroxyurea that retards the natural age-related fall in HbF.87”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508
Self-citationThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Self-citationVoskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 406
Self-citationZimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2003) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 312
Self-citationSystematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
Lanzkron, S., Strouse, J. J., Wilson, R. F., Beach, M. C., Haywood, C., Park, H., Witkop, C., Bass, E. B., & Segal, J. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00221 · Cited by 288
Cited by
Sorted by citations
Items 101–200 of 796
McGann, P. T., Tshilolo, L. M., Santos, B., TOMLINSON, G. A., Stuber, S. E., Latham, T., Aygün, B., Obaro, S., Olupot‐Olupot, P., Williams, T. N., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25705 · Cited by 67
Self-citationParental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Oyeku, S. O., Driscoll, M. C., Cohen, H. W., Trachtman, R. A., Pashankar, F., Mullen, C. A., Giardina, P. J., Velazco, N. K., Racine, A. D., & Green, N. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24381 · Cited by 66
Stroke in patients with sickle cell disease
Webb, J. L., & Kwiatkowski, J. L. (2013) · Expert Review of Hematology · doi:10.1586/ehm.13.25 · Cited by 66
Emerging science of hydroxyurea therapy for pediatric sickle cell disease
Green, N., & Barral, S. (2013) · Pediatric Research · doi:10.1038/pr.2013.227 · Cited by 66
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Walker, A. L., Steward, S. A., Howard, T. A., Mortier, N. A., Smeltzer, M. P., Wang, Y., & Ware, R. E. (2011) · Blood · doi:10.1182/blood-2011-07-368746 · Cited by 65
Self-citationThinking beyond sickling to better understand pain in sickle cell disease
Darbari, D. S., Ballas, S. K., & Clauw, D. J. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12340 · Cited by 65
Balandya, E., Reynolds, T. A., Obaro, S., & Makani, J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24438 · Cited by 66
Fitzhugh, C. D., Hsieh, M. M., Allen, D., Coles, W. A., Seamon, C., Ring, M., Zhao, X., Minniti, C. P., Rodgers, G. P., Schechter, A. N., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141706 · Cited by 64
Self-citationClinical management of adult sickle-cell disease
Bartolucci, P., & Galactéros, F. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328351c35f · Cited by 64
Optimizing hydroxyurea therapy for sickle cell anemia
Ware, R. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.436 · Cited by 68
Self-citationEffective use of hydroxyurea for sickle cell anemia in low-resource countries
Power‐Hays, A., & Ware, R. E. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000582 · Cited by 62
Self-citationWeight Status of Children With Sickle Cell Disease
Chawla, A., Sprinz, P. G., Welch, J. J. G., Heeney, M. M., Usmani, N., Pashankar, F., & Kavanagh, P. L. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2225 · Cited by 62
Estepp, J. H., Smeltzer, M. P., Wang, W. C., Hoehn, M. E., Hankins, J. S., & Aygün, B. (2013) · British Journal of Haematology · doi:10.1111/bjh.12238 · Cited by 61
Self-citationHydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children
Brousseau, D. C., Richardson, T., Hall, M., Ellison, A. M., Shah, S. S., Raphael, J. L., Bundy, D. G., & Arnold, S. D. (2019) · PEDIATRICS · doi:10.1542/peds.2018-3285 · Cited by 60
Alberts, N. M., Badawy, S. M., Hodges, J., Estepp, J. H., Nwosu, C., Khan, H., Smeltzer, M. P., Homayouni, R., Norell, S., Klesges, L. M., et al. (2020) · JMIR mhealth and uhealth · doi:10.2196/14884 · Cited by 60
Pediatric sickle cell disease: past successes and future challenges
Meier, E. R., & Rampersad, A. G. (2016) · Pediatric Research · doi:10.1038/pr.2016.204 · Cited by 59
Sickle cell disease: time for a closer look at treatment options?
Sheth, S., Licursi, M., & Bhatia, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12413 · Cited by 57
Ballas, S. K. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189002 · Cited by 61
Rigano, P., Franceschi, L. D., Sainati, L., Piga, A. G., Piel, F. B., Cappellini, M. D., Fidone, C., Masera, N., Palazzi, G., Gianesin, B., et al. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.017 · Cited by 56
Developmental Function in Toddlers With Sickle Cell Anemia
Armstrong, F. D., Elkin, T. D., Brown, C., Glass, P., RANA, S. R., Casella, J. F., Kalpatthi, R. V., Pavlakis, S. G., Mi, Z., Wang, W. C., et al. (2013) · PEDIATRICS · doi:10.1542/peds.2012-0283 · Cited by 56
Self-citationStem cell transplantation after reduced‐intensity conditioning for sickle cell disease
Matthes‐Martin, S., Lawitschka, Á., Fritsch, G., Lion, T., Grimm, B., Breuer, S. K., Boztug, H., Karlhuber, S., Holter, W., Peters, C., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12082 · Cited by 56
Arnold, S. D., Bhatia, M., Horan, J., & Krishnamurti, L. (2016) · British Journal of Haematology · doi:10.1111/bjh.14167 · Cited by 58
Treatment Options for Sickle Cell Disease
Meier, E. R. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.005 · Cited by 62
Immunologic Effects of Hydroxyurea in Sickle Cell Anemia
Lederman, H. M., Connolly, M. A., Kalpatthi, R. V., Ware, R. E., Wang, W. C., Luchtman‐Jones, L., Waclawiw, M. A., Goldsmith, J. C., Swift, A. J., & Casella, J. F. (2014) · PEDIATRICS · doi:10.1542/peds.2014-0571 · Cited by 55
Self-citationDong, M., McGann, P. T., Mizuno, T., Ware, R. E., & Vinks, A. A. T. M. M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12851 · Cited by 56
Self-citationMcClish, D. K., Smith, W. R., Levenson, J. L., Aisiku, I. P., Roberts, J. D., Roseff, S. D., & Bovbjerg, V. E. (2017) · BioMed Research International · doi:10.1155/2017/4070547 · Cited by 55
Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease
Badawy, S. M., Thompson, A. A., Holl, J. L., Penedo, F. J., & Liem, R. I. (2018) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2018.1505988 · Cited by 56
Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges
Hulbert, M. L., & Shenoy, S. S. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27263 · Cited by 55
McArthur, J. G., Svenstrup, N., Chen, C., Fricot, A., Carvalho, C., Nguyen, J., Nguyen, P., Parachikova, A. I., Abdulla, F. A., Vercellotti, G. M., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.213462 · Cited by 56
Current Management of Sickle Cell AnemiaPreprint
McGann, P. T., Nero, A. C., & Ware, R. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011817 · Cited by 54
Self-citationThomas, R., Dulman, R. Y., Lewis, A., Notarangelo, B., & Yang, E. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27816 · Cited by 54
Standard management of sickle cell disease complications ☆
Abboud, M. R. (2020) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2019.12.007 · Cited by 56
Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion
Patel, S. R., Gibb, D. R., Girard‐Pierce, K. R., Zhou, X., Rodrigues, L. C., Arthur, C. M., Bennett, A. L., Jajosky, R. P., Fuller, M., Maier, C. L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02516 · Cited by 52
Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia
Estepp, J. H., Winter, B., Johnson, M. R., Smeltzer, M. P., Howard, S. C., & Hankins, J. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25177 · Cited by 52
McCavit, T. L. (2012) · Pediatrics in Review · doi:10.1542/pir.33-5-195 · Cited by 52
Outcomes of Acute Chest Syndrome in Adult Patients with Sickle Cell Disease: Predictors of Mortality
Allareddy, V., Roy, A., Lee, M. K., Nalliah, R. P., Rampa, S., Allareddy, V., & Rotta, A. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094387 · Cited by 52
Russo, G. M., Franceschi, L. D., Colombatti, R., Rigano, P., Perrotta, S., Voi, V., Palazzi, G., Fidone, C., Quota, A., Graziadei, G., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1099-0 · Cited by 53
THE EVOLVING PHARMACOTHERAPEUTIC LANDSCAPE FOR THE TREATMENT OF SICKLE CELL DISEASE
Ballas, S. K. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.010 · Cited by 52
Galadanci, N. A., Abdullahi, S. U., Abubakar, S. A., Jibir, B. W., Aminu, H., Tijjani, A., Abba, M. A., Tabari, M. A., Galadanci, A. A., Borodo, A. M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25900 · Cited by 52
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
Osunkwo, I., Manwani, D. G., & Kanter, J. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720955000 · Cited by 57
How I treat the older adult with sickle cell disease
Thein, S. L., & Howard, J. (2018) · Blood · doi:10.1182/blood-2018-03-818161 · Cited by 53
MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease
Li, Y., Zhu, X., Ward, C. M., Starlard‐Davenport, A., Takezaki, M., Berry, A., Ward, A., Wilder, C., Neunert, C. E., Kutlar, A., et al. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.11.002 · Cited by 51
Self-citationAlvarez, O. A., Yovetich, N. A., Scott, J. P., Owen, W. C., Miller, S. T., Schultz, W. H., Lockhart, A., Aygün, B., Flanagan, J. M., Bonner, M. J., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23547 · Cited by 50
Self-citationTreadwell, M. J., Du, L., Bhasin, N., Marsh, A., Wun, T., Bender, M. A., Wong, T. E., Crook, N., Chung, J. H., Norman, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.921432 · Cited by 54
Clinical Pharmacology of Deferasirox
Tanaka, C. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0151-4 · Cited by 49
Jain, D. L., Apte, M., Colah, R. B., Sarathi, V., Desai, S., Gokhale, A., Bhandarwar, A., Jain, H., & Ghosh, K. (2013) · Indian Pediatrics · doi:10.1007/s13312-013-0264-0 · Cited by 49
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Demirci, S., Leonard, A. K., Essawi, K., & Tisdale, J. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.010 · Cited by 56
Strouse, J. J. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00018-5 · Cited by 48
Colombatti, R., Bon, E. D., Bertomoro, A., Casonato, A., Pontara, E., Omenetto, E., Saggiorato, G., Steffan, A., Damian, T., Cella, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078801 · Cited by 47
Prospects for primary stroke prevention in children with sickle cell anaemia
Jordan, L. C., Casella, J. F., & DeBaun, M. R. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09005.x · Cited by 47
Self-citation2015 Clinical trials update in sickle cell anemia
Archer, N. M., Galactéros, F., & Brugnara, C. (2015) · American Journal of Hematology · doi:10.1002/ajh.24116 · Cited by 49
Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease
Chonat, S., & Quinn, C. T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_3 · Cited by 48
Dampier, C., Ely, B., Brodecki, D., Coleman, C., Aertker, L., Sendecki, J. A., Leiby, B. E., Kesler, K. L., Hyslop, T., & Stuart, M. J. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24796 · Cited by 46
Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives
de Azevedo, J. T. C., & Malmegrim, K. C. R. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.04.012 · Cited by 46
Fortin, P. M., Hopewell, S., & Estcourt, L. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012082.pub2 · Cited by 47
Nickel, R. S., Osunkwo, I., Garrett, A. P., Robertson, J. M., Archer, D. R., Promislow, D., Horan, J., Hendrickson, J. E., & Kean, L. S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13326 · Cited by 45
McGann, P. T., Flanagan, J. M., Howard, T. A., Dertinger, S. D., He, J., Kulharya, A. S., Thompson, B. W., Ware, R. E., & for the BABY HUG Investigators (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23365 · Cited by 45
Self-citationAdvances in the Diagnosis and Treatment of Pediatric Arterial Ischemic Stroke
Sun, L. R., & Lynch, J. K. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01373-5 · Cited by 44
Lebensburger, J. D., Sidonio, R. F., DeBaun, M. R., Safford, M. M., Howard, T. H., & Scarinci, I. C. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24486 · Cited by 44
Self-citationColombatti, R., Perrotta, S., Samperi, P., Casale, M., Masera, N., Palazzi, G., Sainati, L., & Russo, G. M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-169 · Cited by 44
Badawy, S. M., Barrera, L., Cai, S. W., & Thompson, A. A. (2018) · BioMed Research International · doi:10.1155/2018/8296139 · Cited by 45
How I manage cerebral vasculopathy in children with sickle cell disease
Brousse, V. A. M., Kossorotoff, M., & de Montalembert, M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13477 · Cited by 43
Vichinsky, E. P., Torres, M. D., Minniti, C. P., Barrette, S., Habr, D., Zhang, Y., Files, B. A., & on behalf of the study CICL670A2201 investigators (2013) · American Journal of Hematology · doi:10.1002/ajh.23569 · Cited by 43
Self-citationLagunju, I. A., Brown, B. J., Oyinlade, A. O., Asinobi, A. O., Ibeh, J. N., Esione, A., & Sodeinde, O. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27252 · Cited by 43
Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice
Kasztan, M., Fox, B. M., Lebensburger, J. D., Hyndman, K. A., Speed, J. S., Pollock, J. S., & Pollock, D. M. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028878 · Cited by 43
Drug Therapies for the Management of Sickle Cell Disease
Rai, P., & Ataga, K. I. (2020) · F1000Research · doi:10.12688/f1000research.22433.1 · Cited by 43
Mulaku, M., Opiyo, N., Karumbi, J., Kitonyi, G., Thoithi, G. N., & English, M. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-302387 · Cited by 43
Evidence gaps in the management of sickle cell disease: A summary of needed research
Savage, W. J., Buchanan, G. R., Yawn, B. P., Afenyi‐Annan, A., Ballas, S. K., Goldsmith, J. C., Hassell, K. L., James, A., John‐Sowah, J., Jordan, L. B., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23945 · Cited by 43
Self-citationPrevalence of acute kidney injury during pediatric admissions for acute chest syndrome
Lebensburger, J. D., Palabindela, P., Howard, T. H., Feig, D. I., Aban, I., & Askenazi, D. J. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3370-0 · Cited by 42
Self-citationBakshi, N., Sinha, C. B., Ross, D. C., Khemani, K., Loewenstein, G. F., & Krishnamurti, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178413 · Cited by 42
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE
Mattè, A., Mazzi, F., Federti, E., Olivieri, O., & Franceschi, L. D. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.002 · Cited by 46
da Guarda, C. C., Silveira-Mattos, P. S., Yahouédéhou, S. C. M. A., Santiago, R. P., Aleluia, M. M., Figueiredo, C. V. B., Fiuza, L. M., Carvalho, S. P., de Oliveira, R. M., Nascimento, V. M. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51339-x · Cited by 42
Inpatient management of sickle cell pain: A ‘snapshot’ of current practice
Miller, S. T., Kim, H., Weiner, D. L., Wager, C. G., Gallagher, D. M., Styles, L. A., & Dampier, C. (2011) · American Journal of Hematology · doi:10.1002/ajh.22265 · Cited by 41
Self-citationPrevalence of Developmental Delay and Contributing Factors Among Children With Sickle Cell Disease
Hoyt, C. R., Abel, R., Gabir, M., Farmer, G. W., & King, A. A. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25838 · Cited by 41
Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease
Brodsky, M. A., Rodeghier, M., Sanger, M., Byrd, J., McClain, B. L., Covert, B. V., Roberts, D. O., Wilkerson, K., DeBaun, M. R., & Kassim, A. A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.12.010 · Cited by 41
Emerging therapies in sickle cell disease
Nardo‐Marino, A., Brousse, V. A. M., & Rees, D. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.16504 · Cited by 42
How we prevent and manage infection in sickle cell disease
Sobota, A. E., Sabharwal, V., Fonebi, G., & Steinberg, M. H. (2015) · British Journal of Haematology · doi:10.1111/bjh.13526 · Cited by 41
Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State
Anders, D. G., Tang, F., Ledneva, T., Caggana, M., Green, N., Wang, Y., & Sturman, L. S. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.01.001 · Cited by 41
Ofakunrin, A. O. D., Oguche, S., Adekola, K., Okpe, E. S., Afolaranmi, T., Diaku-Akinwumi, I., Zoakah, A., & Sagay, A. S. (2019) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmz070 · Cited by 41
Hydroxyurea and Growth in Young Children With Sickle Cell Disease
RANA, S. R., Houston, P. E., Wang, W. C., Iyer, R. V., Goldsmith, J. C., Casella, J. F., Reed, C. K., Rogers, Z. R., Waclawiw, M. A., & Thompson, B. (2014) · PEDIATRICS · doi:10.1542/peds.2014-0917 · Cited by 40
Self-citationThe Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia
Rubio, M. L., & Marina, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216404 · Cited by 44
Targeted Fetal Hemoglobin Induction for Treatment of Beta Hemoglobinopathies
Perrine, S. P., Pace, B. S., & Faller, D. V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.11.009 · Cited by 39
Okam, M. M., Shaykevich, S., Ebert, B. L., Zaslavsky, A. M., & Ayanian, J. Z. (2014) · Medical Care · doi:10.1097/mlr.0000000000000143 · Cited by 39
Estcourt, L. J., Fortin, P. M., Hopewell, S., & Trivella, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012082 · Cited by 39
Bello‐Manga, H., DeBaun, M. R., & Kassim, A. A. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1240612 · Cited by 39
The epidemiology of sickle cell disease in Germany following recent large-scale immigration
Kunz, J. B., Cario, H., Grosse, R., Jarisch, A., Lobitz, S., & Kulozik, A. E. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26550 · Cited by 39
Guilliams, K. P., Fields, M. E., & Dowling, M. M. (2019) · Stroke · doi:10.1161/strokeaha.118.020482 · Cited by 39
Partanen, M., Kang, G., Wang, W. C., Krull, K. R., King, A. A., Schreiber, J. E., Porter, J. S., Hodges, J., Hankins, J. S., & Jacola, L. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16519 · Cited by 39
Self-citationSommet, J., Alberti, C., Couque, N., Verlhac, S., Haouari, Z., Mohamed, D., François, M., Missud, F., Holvoet, L., Elmaleh, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13916 · Cited by 38
Nottage, K. A., Ware, R. E., Winter, B., Smeltzer, M. P., Wang, W. C., Hankins, J. S., Dertinger, S. D., Shulkin, B. L., & Aygün, B. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12361 · Cited by 38
Self-citationHankins, J. S., Penkert, R. R., Lavoie, P. T., Tang, L., Sun, Y., & Hurwitz, J. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216636723 · Cited by 38
Tuijn, C. F. J. V., Schimmel, M., van Beers, E. J., Nur, E., & Biemond, B. J. (2017) · American Journal of Hematology · doi:10.1002/ajh.24855 · Cited by 38
Opoka, R. O., Hume, H. A., Latham, T., Lane, A., Williams, O., Tymon, J., Nakafeero, M., Kasirye, P., Ndugwa, C. M., John, C. C., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.231407 · Cited by 36
Self-citationMcGann, P. T., Williams, T. N., Olupot‐Olupot, P., TOMLINSON, G. A., Lane, A., da Fonseca, J. L. R., Kitenge, R., Mochamah, G., Wabwire, H., Stuber, S. E., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25034 · Cited by 37
Self-citationDaak, A. A., Dampier, C., Fuh, B., Kanter, J., Alvarez, O. A., Black, L. V., McNaull, M. A., Callaghan, M. U., George, A., Neumayr, L., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021444 · Cited by 37
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 40
Esrick, E. B., McConkey, M. E., Lin, K. I., Frisbee, A. L., & Ebert, B. L. (2015) · American Journal of Hematology · doi:10.1002/ajh.24019 · Cited by 35
Kunz, J. B., Awad, S., Happich, M., Muckenthaler, L., Lindner, M. S., Gramer, G., Okun, J. G., Hoffmann, G. F., Bruckner, T. M., Muckenthaler, M. U., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2573-y · Cited by 36
Brandow, A. M., Hansen, K., Nugent, M., Pan, A. Y., Panepinto, J. A., & Stucky, C. L. (2018) · Pain · doi:10.1097/j.pain.0000000000001407 · Cited by 36
Metadata
- Authors
- Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., Barredo, J. C., Brown, R. C., Sarnaik, S. A., Howard, T. H., Wynn, L. W., Kutlar, A., Armstrong, F. D., Files, B. A., Goldsmith, J. C., Waclawiw, M. A., Huang, X., & Thompson, B. W.
- Affiliations
- St. Jude Children's Research Hospital (US)
- SUNY Downstate Health Sciences University (US)
- University of Mississippi Medical Center (US)
- Johns Hopkins University (US)
- Children's National (US)
- Howard University (US)
- Duke Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Medical University of South Carolina (US)
- University of Miami (US)
- Children's Hospital of Michigan (US)
- University of Alabama at Birmingham (US)
- Augusta University (US)
- Emory University (US)
- National Heart, Lung, and Blood Institute (US)
- Clinical Trials and Surveys Corporation (US)
- Corresponding author
- Wang, Winfred C
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 377
- Issue
- 9778
- Pages
- 1663-1672
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3133619
- OpenAlex
- W2170086069
- Semantic Scholar
- 007f7341f1586c3f34ecd96fa415bd95116f1c85
- Cited by
- 803
- References
- 35
- Citations by year
- 2026: 46 · 2025: 42 · 2024: 57 · 2023: 49 · 2022: 58 · 2021: 54 · 2020: 58 · 2019: 67 · 2018: 50 · 2017: 64 · 2016: 52 · 2015: 61 · 2014: 50 · 2013: 45 · 2012: 25
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hb07156-19-0-1, n01hb07159-25-0-1, n01hb07153-18-0-1, n01hb07155-16-0-0, n01hb07158-17-0-0, n01hb07157-15-0-0, n01hb07152-18-0-0, n01hb07151-17-0-0, n01hb07150-20-0-1, n01hb07160-38-0-1, n01hb07154-21-0-0)
- National Heart, Lung, and Blood Institute (N01-HB-07154, N01-HB-07157, N01-HB-07160, N01 HB007155, N01-HB07155, N01-HB-07152, N01-HB-07153, N01 HB007150, N01-HB-07151, N01-HB-07158, N01-HB-07150, N01 HB007160, N01-HB-07159, N01-HB-07156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- hydroxyurea, sickle cell disease, infants, spleen function, renal function, acute chest syndrome, pain episodes, fetal hemoglobin, brain development, mutagenicity, drug toxicity, beta-thalassemia, organ dysfunction, growth, transcranial Doppler, glomerular filtration rate, urine osmolality
- MeSH terms
- Anemia, Sickle Cell, Antisickling Agents, Blood Cell Count, Child Development, Female, Glomerular Filtration Rate, Hemoglobins, Humans, Hydroxyurea, Infant, Male, Osmolar Concentration, Pain, Spleen, United States, Urine, Biomarkers, Technetium Tc 99m Pentetate, Treatment Outcome, Ultrasonography, Doppler, Transcranial, Acute Chest Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
